Haemonetics (HAE) Expected to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is anticipated to issue its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $331.8980 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same period last year, the business earned $1.12 EPS. Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Trading Down 1.2%

Shares of Haemonetics stock opened at $65.83 on Tuesday. The firm’s 50 day simple moving average is $78.20 and its two-hundred day simple moving average is $65.32. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 1.38 and a beta of 0.28. Haemonetics has a 12-month low of $47.31 and a 12-month high of $87.32. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Analyst Ratings Changes

HAE has been the topic of several research reports. Raymond James Financial reissued an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Robert W. Baird raised their price objective on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Barrington Research reiterated an “outperform” rating and issued a $93.00 target price on shares of Haemonetics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.40.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after acquiring an additional 971 shares during the period. Caxton Associates LLP purchased a new position in shares of Haemonetics during the 1st quarter valued at approximately $216,000. United Services Automobile Association purchased a new position in shares of Haemonetics during the 1st quarter valued at approximately $212,000. Empowered Funds LLC lifted its stake in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after buying an additional 9,051 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.